Loading
Latest filing published 10 Aug 2026 for Corbus Pharmaceuticals Holdings, Inc., €149k.
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Yuval Cohen is a declared insider of Corbus Pharmaceuticals Holdings, Inc. (chief executive), with filings sourced from SEC (Form 4). Between 3 December 2014 and 7 August 2026, the trades on record add up to 55 filings.
On the open market, the record shows 27 purchases worth €141k and 13 sales worth €3.5M. On balance, insiders were net sellers of €3.3M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 3 share grants and 12 option exercises. 2026 to date brings no purchases and 2 sales.
Half of the purchases are above €4,409 and half below. Clusters matter here: 14 out of 17 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.
On 10 August 2026 came the latest disclosure, an open-market sale for €149k in Corbus Pharmaceuticals Holdings, Inc. The last insider purchase was made public on 11 August 2022, 1,535 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations